Related Experiment Video
Updated: Dec 10, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial
Akira Takazawa1,2, Satoshi Morita3
1Data Science Department, ONO Pharmaceutical Co., Ltd, 8-2, Kyutaromachi 1-Chome, Chuo-ku, Osaka, 541-8564, Japan. takazawa@ono.co.jp.
Abstract:
In the original article in the section "Application to the Motivating Example", Greenberg's trial data have been deleted from the historical data.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Clinical Trials: Overview
Dose Size and Dosing Frequency: Determination Methods